Core Polarization and Tensor Coupling Effects on Magnetic Moments of Hypernuclei

The effects of core polarization and tensor coupling on the magnetic moments in $^{13}_\Lambda$C, $^{17}_\Lambda$O, and $^{41}_\Lambda$Ca $\Lambda$-hypernuclei are studied in the Dirac equation with scalar, vector and tensor potentials. It is found that the effect of core polarization on the magnetic moments is suppressed by $\Lambda$ tensor coupling. The $\Lambda$ tensor potential reduces the spin-orbit splitting of $p_\Lambda$ states considerably. However, almost the same magnetic moments are obtained using the hyperon wave function obtained via the Dirac equation either with or without the $\Lambda$ tensor potential in the electromagnetic current vertex. The deviations of magnetic moments for $p_\Lambda$ states from the Schmidt values are found to increase with nuclear mass number.Comment: 10 pages, 2 figures, 2 table

A systematic study on the binding energy of Λ\Lambda hypernuclei

In this paper, we calculated the binding energy per baryon of the $\Lambda$ hypernuclei systemically, using the relativistic mean field theory (RMF) in a statistic frame. Some resemble properties are found among most of the hypernuclei found in experiments. The data show that a $\Lambda$ hypernucleus will be more stable, if it is composed of a $\Lambda$ hyperon adding to a stable normal nuclear core, or a $\Lambda$ hyperon replacing a neutron in a stable normal nuclear core. According to our calculations, existences of some new $\Lambda$ hypernuclei are predicted under the frame of RMF.Comment: 8 pages, 6 figures, 3 table

Pharmacodynamics of Memantine: An Update

Memantine received marketing authorization from the European Agency for the Evaluation of Medicinal Products (EMEA) for the treatment of moderately severe to severe Alzheimer´s disease (AD) in Europe on 17th May 2002 and shortly thereafter was also approved by the FDA for use in the same indication in the USA. Memantine is a moderate affinity, uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist with strong voltage-dependency and fast kinetics. Due to this mechanism of action (MOA), there is a wealth of other possible therapeutic indications for memantine and numerous preclinical data in animal models support this assumption. This review is intended to provide an update on preclinical studies on the pharmacodynamics of memantine, with an additional focus on animal models of diseases aside from the approved indication. For most studies prior to 1999, the reader is referred to a previous review [196]

Double Λ\Lambda and the Λ−Λ\Lambda-\Lambda Interaction

The $\Lambda$-$\Lambda$ effective interaction, in the channel $L=S=0$, in the nuclear medium is fitted to the available binding energies, $B_{\Lambda\Lambda}$, of double $\Lambda$ hypernuclei: $^{6}_{\Lambda\Lambda}$He, $^{10}_{\Lambda\Lambda}$Be and $^{13}_{\Lambda\Lambda}$B. The mesonic decay of these hypernuclei is also investigated. Finally, this effective interaction is used to predict the binding energies and mesonic decays widths of heavier double $\Lambda$ hypernuclei.Comment: 4 pages, (latex file, postscript-file and 3 Postscript-figures included

Observation of hypertritons in Au+Au collisions at \sqrt{s_{NN}} = 200 GeV

We report preliminary results of hypertriton observation in heavy-ion collisions at RHIC. We have identified 157 +- 30 candidates in the current sample containing ~10^8 Au+Au events at \sqrt{s_{NN}} = 200 GeV. The production rate of hypertriton is close to that of helium 3. No extra penalty factor is observed for hypertriton, in contrast to results observed at the AGS.Comment: Turn off the line number package for QM09 proceeding publicatio

Memantine and Cholinesterase Inhibitors: Complementary Mechanisms in the Treatment of Alzheimer’s Disease

This review describes the preclinical mechanisms that may underlie the increased therapeutic benefit of combination therapy—with the N-methyl-d-aspartate receptor antagonist, memantine, and an acetylcholinesterase inhibitor (AChEI)—for the treatment of Alzheimer’s disease (AD). Memantine, and the AChEIs target two different aspects of AD pathology. Both drug types have shown significant efficacy as monotherapies for the treatment of AD. Furthermore, clinical observations indicate that their complementary mechanisms offer superior benefit as combination therapy. Based on the available literature, the authors have considered the preclinical mechanisms that could underlie such a combined approach. Memantine addresses dysfunction in glutamatergic transmission, while the AChEIs serve to increase pathologically lowered levels of the neurotransmitter acetylcholine. In addition, preclinical studies have shown that memantine has neuroprotective effects, acting to prevent glutamatergic over-stimulation and the resulting neurotoxicity. Interrelations between the glutamatergic and cholinergic pathways in regions of the brain that control learning and memory mean that combination treatment has the potential for a complex influence on disease pathology. Moreover, studies in animal models have shown that the combined use of memantine and the AChEIs can produce greater improvements in measures of memory than either treatment alone. As an effective approach in the clinical setting, combination therapy with memantine and an AChEI has been a welcome advance for the treatment of patients with AD. Preclinical data have shown how these drugs act via two different, but interconnected, pathological pathways, and that their complementary activity may produce greater effects than either drug individually

Further pharmacological characterization of eltoprazine: focus on its anxiolytic, anorexic, and adverse‑effect potential

Eltoprazine, a drug that had previously been developed for aggression, has recently been investigated for L‑DOPA‑induced dyskinesia in animal models of Parkinson´s disease (PD) and in dyskinetic PD patients. Much less is known about effects of eltoprazine in other therapeutic indications. Indeed, the pharmacological profile of eltoprazine might suggest its effects on anxiety and food intake, but also adverse effect potential, which is the focus of the present study. Given for 2 weeks either as infusion or as twice‑daily treatment, eltoprazine produced a decrease in food intake and body weight at doses leading to 200–500 nM plasma concentrations. In the elevated plus maze eltoprazine increased anxiety‑like behavior. On the other hand, it induced a clear‑cut anxiolytic effect in context fear conditioning test starting at ca. 0.3 mg/kg, and failed to produce any significant effect in fear potentiated startle test. Regarding adverse effects, eltoprazine was found to produce hypothermia starting from 1 mg/kg. At similar doses it also increased locomotion in the open field. However, eltoprazine failed to affect acquisition in context fear conditioning paradigm, which may indicate lack of its detrimental effect on learning at the doses tested (i.e., up to 5 mg/kg). In summary, effects of eltoprazine in different anxiety tests were equivocal while its effect on body weight seems robust and requires further investigation. It is to be determined whether these effects can be expected at the doses free of adverse effects

Hypernuclear physics legacy and heritage of Dick Dalitz

The major contributions of Richard H. Dalitz to hypernuclear physics, since his first paper in 1955 to his last one in 2005 covering a span of 50 years during which he founded and led the theoretical study of hypernuclei, are reviewed from a personal perspective. Topical remarks on the search for quasi-bound antikaon-nuclear states and on kaon condensation are made.Comment: prepared for NPA vol. 804 (2008), Recent Advances in Strangeness Nuclear Physics, edited by A. Gal and R.S. Hayano; a preliminary version appeared in the proceedings of HYP0

Antimatter production in proton-proton and heavy-ion collisions at ultrarelativistic energies

One of the striking features of particle production at high beam energies is the near equal abundance of matter and antimatter in the central rapidity region. In this paper we study how this symmetry is reached as the beam energy is increased. In particular, we quantify explicitly the energy dependence of the approach to matter/antimatter symmetry in proton-proton and in heavy-ion collisions. Expectations are presented also for the production of more complex forms of antimatter like antihypernuclei.Comment: 7 pages, 5 figure